Cargando…
The Economic Benefits Resulting from the First 8 Years of the Global Programme to Eliminate Lymphatic Filariasis (2000–2007)
BACKGROUND: Between 2000–2007, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) delivered more than 1.9 billion treatments to nearly 600 million individuals via annual mass drug administration (MDA) of anti-filarial drugs (albendazole, ivermectin, diethylcarbamazine) to all at-risk for...
Autores principales: | Chu, Brian K., Hooper, Pamela J., Bradley, Mark H., McFarland, Deborah A., Ottesen, Eric A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2879371/ https://www.ncbi.nlm.nih.gov/pubmed/20532228 http://dx.doi.org/10.1371/journal.pntd.0000708 |
Ejemplares similares
-
The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)
por: Turner, Hugo C., et al.
Publicado: (2016) -
Investment Success in Public Health: An Analysis of the Cost-Effectiveness and Cost-Benefit of the Global Programme to Eliminate Lymphatic Filariasis
por: Turner, Hugo C., et al.
Publicado: (2017) -
The Global Programme to Eliminate Lymphatic Filariasis: Health Impact after 8 Years
por: Ottesen, Eric A., et al.
Publicado: (2008) -
Assessing Progress in Reducing the At-Risk Population after 13 Years of the Global Programme to Eliminate Lymphatic Filariasis
por: Hooper, Pamela J., et al.
Publicado: (2014) -
A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000–2020)
por: Turner, Hugo C., et al.
Publicado: (2022)